NCT06223841 A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
| NCT ID | NCT06223841 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | SUNHO（China）BioPharmaceutical CO., Ltd. |
| Condition | Advanced Malignant Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-03-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.
Eligibility Criteria
Inclusion Criteria: * 1\. Age 18 to 75years, male or female. * 2\. Phase Ib:With advanced or metastatic malignant solid tumor confirmed by histopathology, the standard treatment fails, or there is no standard treatment plan, or standard treatment is not applicable at this stage, or the patient refuses the standard treatment, or the investigator evaluates the patient who can benefit from this treatment. * 3.Phae II: Confirmed by histopathology that it is not feasible to perform complete resection and cannot be connected. Locally advanced (stage IIIB or IIIC) or metastatic (IV) after radical concurrent radiotherapy and chemotherapy Stage) non-small cell lung cancer (NSCLC). Note: For unacceptable radical synchronization/sequencing.Subjects with locally advanced stage IIIB/IIIC of radiotherapy and chemotherapy need to be evaluated by relevant professional doctors. And provide written records to confirm. * 4.Phae II: Never received systemic anti-tumor therapy for locally advanced or metast